ArticleNPJ breast cancer2026

Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.

Marcin Kubeczko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.